Cargando…
Model‐based meta‐analysis of salbutamol pharmacokinetics and practical implications for doping control
Salbutamol was included in the prohibited list of the World Anti‐Doping Agency (WADA) in 2004. Although systemic intake is banned, inhalation for asthma is permitted but with dosage restrictions. The WADA established a urinary concentration threshold to distinguish accordingly prohibited systemic se...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007606/ https://www.ncbi.nlm.nih.gov/pubmed/35315251 http://dx.doi.org/10.1002/psp4.12773 |
_version_ | 1784686885500616704 |
---|---|
author | Courlet, Perrine Buclin, Thierry Biollaz, Jérôme Mazzoni, Irene Rabin, Olivier Guidi, Monia |
author_facet | Courlet, Perrine Buclin, Thierry Biollaz, Jérôme Mazzoni, Irene Rabin, Olivier Guidi, Monia |
author_sort | Courlet, Perrine |
collection | PubMed |
description | Salbutamol was included in the prohibited list of the World Anti‐Doping Agency (WADA) in 2004. Although systemic intake is banned, inhalation for asthma is permitted but with dosage restrictions. The WADA established a urinary concentration threshold to distinguish accordingly prohibited systemic self‐administration from therapeutic prescription by inhalation. This study aimed at evaluating the ability of the WADA threshold to differentiate salbutamol therapeutic use from violation of antidoping rules. Concentration‐time profile of salbutamol in plasma and its excretion in urine was characterized through a model‐based meta‐analysis of individual and aggregate data collected after administration of a large range of doses following different modes of administration and under a variety of conditions. The developed model adequately fitted salbutamol plasma and urine concentration‐time profiles of the 13 selected studies. Model‐based simulations confirmed that a wide range of salbutamol urine concentrations might be measured after drug intake. Although violation of the WADA Code can be strongly suspected in individuals showing very high salbutamol urine concentrations, uncertainty remains for values close to the WADA threshold as they can be compatible with both permitted therapeutic use and violation. Although not entirely discriminant, the current WADA rule is globally supported by our appraisal. It could be further improved by a slight and reasonable adjustment of inhaled daily dosages allowed for therapeutic use. Our model might help antidoping experts in the evaluation of suspected doping cases through confronting the athlete's urine measurements with their allegations about salbutamol treatment. |
format | Online Article Text |
id | pubmed-9007606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90076062022-04-15 Model‐based meta‐analysis of salbutamol pharmacokinetics and practical implications for doping control Courlet, Perrine Buclin, Thierry Biollaz, Jérôme Mazzoni, Irene Rabin, Olivier Guidi, Monia CPT Pharmacometrics Syst Pharmacol Research Salbutamol was included in the prohibited list of the World Anti‐Doping Agency (WADA) in 2004. Although systemic intake is banned, inhalation for asthma is permitted but with dosage restrictions. The WADA established a urinary concentration threshold to distinguish accordingly prohibited systemic self‐administration from therapeutic prescription by inhalation. This study aimed at evaluating the ability of the WADA threshold to differentiate salbutamol therapeutic use from violation of antidoping rules. Concentration‐time profile of salbutamol in plasma and its excretion in urine was characterized through a model‐based meta‐analysis of individual and aggregate data collected after administration of a large range of doses following different modes of administration and under a variety of conditions. The developed model adequately fitted salbutamol plasma and urine concentration‐time profiles of the 13 selected studies. Model‐based simulations confirmed that a wide range of salbutamol urine concentrations might be measured after drug intake. Although violation of the WADA Code can be strongly suspected in individuals showing very high salbutamol urine concentrations, uncertainty remains for values close to the WADA threshold as they can be compatible with both permitted therapeutic use and violation. Although not entirely discriminant, the current WADA rule is globally supported by our appraisal. It could be further improved by a slight and reasonable adjustment of inhaled daily dosages allowed for therapeutic use. Our model might help antidoping experts in the evaluation of suspected doping cases through confronting the athlete's urine measurements with their allegations about salbutamol treatment. John Wiley and Sons Inc. 2022-03-22 2022-04 /pmc/articles/PMC9007606/ /pubmed/35315251 http://dx.doi.org/10.1002/psp4.12773 Text en © 2022 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Courlet, Perrine Buclin, Thierry Biollaz, Jérôme Mazzoni, Irene Rabin, Olivier Guidi, Monia Model‐based meta‐analysis of salbutamol pharmacokinetics and practical implications for doping control |
title | Model‐based meta‐analysis of salbutamol pharmacokinetics and practical implications for doping control |
title_full | Model‐based meta‐analysis of salbutamol pharmacokinetics and practical implications for doping control |
title_fullStr | Model‐based meta‐analysis of salbutamol pharmacokinetics and practical implications for doping control |
title_full_unstemmed | Model‐based meta‐analysis of salbutamol pharmacokinetics and practical implications for doping control |
title_short | Model‐based meta‐analysis of salbutamol pharmacokinetics and practical implications for doping control |
title_sort | model‐based meta‐analysis of salbutamol pharmacokinetics and practical implications for doping control |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007606/ https://www.ncbi.nlm.nih.gov/pubmed/35315251 http://dx.doi.org/10.1002/psp4.12773 |
work_keys_str_mv | AT courletperrine modelbasedmetaanalysisofsalbutamolpharmacokineticsandpracticalimplicationsfordopingcontrol AT buclinthierry modelbasedmetaanalysisofsalbutamolpharmacokineticsandpracticalimplicationsfordopingcontrol AT biollazjerome modelbasedmetaanalysisofsalbutamolpharmacokineticsandpracticalimplicationsfordopingcontrol AT mazzoniirene modelbasedmetaanalysisofsalbutamolpharmacokineticsandpracticalimplicationsfordopingcontrol AT rabinolivier modelbasedmetaanalysisofsalbutamolpharmacokineticsandpracticalimplicationsfordopingcontrol AT guidimonia modelbasedmetaanalysisofsalbutamolpharmacokineticsandpracticalimplicationsfordopingcontrol |